Evidence map›Paper›PMID 36068110›Full record

ArticleVaccine2022

Side effects during the week after first dose vaccination with four Covid-19 vaccines. Results of the ProVaVac Survey Study with 13,837 people in Spain.

Francisco Sánchez-Saez, Salvador Peiró, Llanos Cuenca, Hermelinda Vanaclocha, Ramón Limón, Dolores Salas, Javier S Burgos, José Sánchez-Payá, Ricard Meneu, Javier Díez and 6 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. New-onset aplastic anemia after SARS-CoV-2 vaccination.International journal of hematology · 2023
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Francisco Sánchez-SaezFoundation for the Promotion of Health and Biomedical Research of the Valencia Community (FISABIO), Valencia, Spain.
Salvador PeiróFoundation for the Promotion of Health and Biomedical Research of the Valencia Community (FISABIO), Valencia, Spain.
Llanos CuencaGeneral Directorate for Planning, Technological Efficiency and Patient Care, Department of Health, Valencia Government, Valencia, Spain; Universitat Politècnica de Valencia, UPV.
Hermelinda VanaclochaGeneral Directorate of Public Health, Department of Health, Valencia Government, Valencia, Spain.
Ramón LimónGeneral Directorate of Healthcare, Department of Health, Valencia Government, Valencia, Spain.
Dolores SalasGeneral Directorate of Public Health, Department of Health, Valencia Government, Valencia, Spain.
Javier S BurgosGeneral Directorate of Research and Healthcare Supervision, Department of Health, Valencia Government, Valencia, Spain.
José Sánchez-PayáPreventive Medicine Service, Alicante General and University Hospital, Alicante, Spain; Alicante Institute of Health and Biomedical Research (ISABIAL), Alicante, Spain.
Ricard MeneuGeneral Directorate of Research and Healthcare Supervision, Department of Health, Valencia Government, Valencia, Spain.
Javier DíezFoundation for the Promotion of Health and Biomedical Research of the Valencia Community (FISABIO), Valencia, Spain.
Aníbal García-SempereFoundation for the Promotion of Health and Biomedical Research of the Valencia Community (FISABIO), Valencia, Spain. Electronic address: garcia_ani@gva.es.
Isabel Hurtado NavarroFoundation for the Promotion of Health and Biomedical Research of the Valencia Community (FISABIO), Valencia, Spain.
Clara Rodríguez-BernalFoundation for the Promotion of Health and Biomedical Research of the Valencia Community (FISABIO), Valencia, Spain.
Gabriel Sanfélix-GimenoFoundation for the Promotion of Health and Biomedical Research of the Valencia Community (FISABIO), Valencia, Spain.
David NavarroMicrobiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain; Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain.
Valencian vaccine research program (ProVaVac) study group
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana · ESGeneralitat Valenciana · ESHospital General Universitario de Alicante Doctor Balmis · ESINCLIVA Health Research Institute · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn 2021, four vaccines against Covid-19 (BNT162b2, mRNA-1273, ChAdOx1nCoV-19, and JNJ-78436735) were employed in the region of Valencia, Spain. We conducted a survey to identify real-world, self-reported frequency and severity of side effects during the week after vaccination.

methodsSurvey data was obtained from April 19, 2021, to October 6, 2021, at three different moments in time: day one, day three and day seven after vaccination. Answers were linked to individual-level, personal and clinical information. Respondents were stratified by the vaccine they received and reported effects were presented over time and stratified by severity. We compared our results per vaccine with the frequencies stated in each Summary of Product Characteristics (SmPC). We used binomial logistic models to identify associations between respondent characteristics and side effects.

resultsNo symptoms were reported by 1,986 respondents (14.35 %), 6,254 informed exclusively mild symptoms (45.20 %), 3,444 up to moderate symptoms (24.89 %), and 2,153 people (15.56 %) notified also severe symptoms. Among the latter, the more frequent were extreme tiredness (7.0 %), and nausea or vomiting (7.1 %). The reported frequency of facial paralysis (0.4 %) was much higher than reflected in SmPCs. Female sex, younger age, previous positive Active Infection Diagnostic Test, chronicity, and vaccination with other than the BNT162b2 vaccine were associated to an increased risk of side effects (p < 0.001).

conclusionsSide effects after vaccination are common in the real-world. However, they are principally mild, and their frequency declines after a few days. Providing patients with dependable, beforehand information about side effects may improve outcomes and reinforce vaccination programs.

Indexed as

COVID-19COVID-19 VaccinesDrug-Related Side Effects and Adverse Reactions2019-nCoV Vaccine mRNA-1273Ad26COVS1BNT162 VaccineChAdOx1 nCoV-19FemaleHumansSpainSurveys and QuestionnairesVaccination2019-nCoV Vaccine mRNA-1273Ad26COVS1BNT162 VaccineChAdOx1 nCoV-19COVID-19 VaccinesCovid-19Side effectsSpainSurveyVaccines

Identifiers

PMID36068110
PMCPMC9420721
OpenAlexW4293539877

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.